Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYRRHINIL-INTEST placebo-controlled trial in IBS-D and IBS-M
2024-514892-16-00Phase 4Authorised
- Sponsor
- Repha
- Start
- May 2020
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) and irritable bowel syndrome (IBS) comparing MYRRHINIL-INTEST with Placebo (2 arms). Primary endpoint: Responder endpoint. Planned start May 2020; status: authorised.
02
Drugs
Myrrhinil-Intest
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2024-514892-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514892-16-00.